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Purpose/Objective(s)

Conclusion

Although overall survival for early stage testicular seminoma is
generally excellent, certain pathologic factors can increase recurrence
risk for those undergoing observation, while radiation therapy (RT)
can be associated with long-term morbidity. We sought to identify
disease-related and treatment-related factors that influenced the
outcomes, with particular emphasis on recurrence risk, patterns and
timing of recurrence, as well as RT-induced malignancy.

Although early stage seminoma is associated with excellent longterm results, our study suggests recurrence risk approaches 20% in
patients undergoing observation. Routine follow-up regimens should
be adhered to, especially in the first few years, as most recurrences
occurred within 2 years of treatment. While rates of RT-induced
malignancy were low, these rates may be further improved by
minimizing RT dose and volume.

Material/Methods
With IRB approval, we identified and reviewed medical records
of stage I or II testicular seminoma patients from two institutions
(University of Pennsylvania and Thomas Jefferson University) who
received adjuvant RT or observation between 1979-2009. Patient-,
disease-, and treatment-related variables were obtained including
age, history of undescended testicle, previous inguinal surgery,
date of diagnosis, stage, tumor volume and characteristics, RT dose/
fractionation and volume, disease recurrence, and second malignancy.

Results
A total of 104 patients were identified: 92 with stage I disease and 12
with stage II disease. Median age was 37 years and median follow-up
was 3.2 years. Eighty-one stage I patients underwent adjuvant RT (88%
of study population), while 11 underwent observation (12% of study
population). All stage II patients were treated with adjuvant RT. Total
RT dose ranged from 9-36 Gy (median = 26 Gy). Five patients (4 stage
I, 1 stage II) experienced disease recurrence at a median of 1.7 years
(4.8% of study population). Among stage I patients with recurrence,
2 patients received RT (2.5% of treated population), while 2 patients
were observed (18% of observed population). Local control with
adjuvant RT was 100%, as all recurrences were systemic, outside of
the RT field. Disease-related factors, such as largest tumor dimension,
tumor size, lymphovascular invasion, rete testis and spermatic cord
involvement, and preoperative laboratory markers (LDH, B-HCG)
were not found to be significantly associated with recurrence risk.
Three patients developed a second malignancy within the RT field
(3.3% of treated population) at a median time of 14.6 years. All 3
patients were treated with dogleg field to a median dose of 36 Gy.
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